These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29120964)

  • 1. Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016.
    Brzozowska M; Wierzba W; Śliwczyński A; Świerkowski M; Potemski P; Marczak M
    Melanoma Res; 2018 Feb; 28(1):52-55. PubMed ID: 29120964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival with modern therapeutic agents against metastatic melanoma-vemurafenib and ipilimumab in a daily life setting.
    Lang BM; Peveling-Oberhag A; Faidt D; Hötker AM; Weyer-Elberich V; Grabbe S; Loquai C
    Med Oncol; 2018 Jan; 35(3):24. PubMed ID: 29387968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.
    Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Wysoczański W; Matusewicz W; Kozłowska-Wojciechowska M
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2087-2094. PubMed ID: 28608286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.
    Enewold L; Sharon E; Harlan LC
    Oncol Res Treat; 2017; 40(4):174-183. PubMed ID: 28376479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
    N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data.
    Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Kozłowska-Wojciechowska M
    Eur J Clin Pharmacol; 2019 Mar; 75(3):329-334. PubMed ID: 30386910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
    Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
    Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
    Eggermont AMM; Dummer R
    Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison.
    Galván-Banqueri M; Ubago-Pérez R; Molina-López T
    J Clin Pharm Ther; 2016 Jun; 41(3):285-9. PubMed ID: 27079278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
    Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
    JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
    Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
    J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
    [No Abstract]   [Full Text] [Related]  

  • 16. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
    Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
    Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
    Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting brain metastases in patients with melanoma.
    Papadatos-Pastos D; Soultati A; Harries M
    Biomed Res Int; 2013; 2013():186563. PubMed ID: 24455677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.
    Scholtens A; Geukes Foppen MH; Blank CU; van Thienen JV; van Tinteren H; Haanen JB
    Eur J Cancer; 2015 Mar; 51(5):642-52. PubMed ID: 25690538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J; Larkin J
    Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.